Amgen Chairman, President and CEO Bob Bradway joins 'Mad Money' host Jim Cramer to talk quarterly results, its recent drug trials, what is ahead for the company and more.
Breakdown
- No level of cholesterol is considered good, and only specific drugs can reduce it to insignificant levels.
- Repatha lowered LDL cholesterol to a median of 45 and reduced the risk of a first heart attack by 36% in trial subjects. 16s
- Adding Repatha to optimized therapy prevented first occurrences of heart attack by 36%, reduced stroke risk, and showed a strong signal for preventing cardiac death. 35s
- The trial definitively answered that lower LDL cholesterol is better, with a median of 45 providing meaningful benefit over placebo in patients already on optimal therapy. 1m 13s